Latest Insider Transactions at Ionis Pharmaceuticals Inc (IONS)
This section provides a real-time view of insider transactions for Ionis Pharmaceuticals Inc (IONS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of IONIS PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of IONIS PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 01
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+7.02%
|
-
|
|
Feb 01
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
4,033
+7.21%
|
-
|
|
Feb 01
2024
|
Eric Swayze EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,715
+9.3%
|
-
|
|
Jan 31
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
10,773
-24.89%
|
$560,196
$52.0 P/Share
|
|
Jan 25
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
6,450
-12.11%
|
$328,950
$51.75 P/Share
|
|
Jan 25
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,285
-1.48%
|
$116,535
$51.75 P/Share
|
|
Jan 17
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
5,564
-14.13%
|
$278,200
$50.42 P/Share
|
|
Jan 17
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
7,744
-12.7%
|
$387,200
$50.42 P/Share
|
|
Jan 17
2024
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
4,497
-9.16%
|
$224,850
$50.42 P/Share
|
|
Jan 17
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,338
-7.91%
|
$366,900
$50.42 P/Share
|
|
Jan 17
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
8,683
-8.72%
|
$434,150
$50.42 P/Share
|
|
Jan 17
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
32,059
-17.22%
|
$1,602,950
$50.42 P/Share
|
|
Jan 17
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
5,482
-10.28%
|
$274,100
$50.42 P/Share
|
|
Jan 17
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Indirect |
9
-9.57%
|
$450
$50.42 P/Share
|
|
Jan 17
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
6,296
-12.7%
|
$314,800
$50.42 P/Share
|
|
Jan 17
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Indirect |
564
-25.59%
|
$28,200
$50.42 P/Share
|
|
Jan 17
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,460
-10.24%
|
$73,000
$50.42 P/Share
|
|
Jan 17
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,745
-8.02%
|
$337,250
$50.42 P/Share
|
|
Jan 16
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
15,062
+27.67%
|
-
|
|
Jan 16
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,641
+25.28%
|
-
|
|
Jan 16
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
12,080
+19.75%
|
-
|
|
Jan 16
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,852
+17.62%
|
-
|
|
Jan 16
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,487
+18.42%
|
-
|
|
Jan 16
2024
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,084
+26.78%
|
-
|
|
Jan 16
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
15,162
+22.14%
|
-
|
|
Jan 16
2024
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Indirect |
21
+18.26%
|
-
|
|
Jan 16
2024
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
17,069
+25.61%
|
-
|
|
Jan 16
2024
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,353
+38.04%
|
-
|
|
Jan 16
2024
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,688
+20.55%
|
-
|
|
Jan 16
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,314
+17.89%
|
-
|
|
Jan 12
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
8,000
-17.33%
|
$424,000
$53.5 P/Share
|
|
Jan 12
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+14.77%
|
$256,000
$32.6 P/Share
|
|
Dec 28
2023
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
27,100
-45.46%
|
$1,355,000
$50.19 P/Share
|
|
Dec 28
2023
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
27,100
+31.25%
|
$1,273,700
$47.34 P/Share
|
|
Dec 28
2023
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Payment of exercise price or tax liability
|
Direct |
11,029
-22.96%
|
$551,450
$50.5 P/Share
|
|
Dec 28
2023
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
11,500
+19.32%
|
$540,500
$47.34 P/Share
|
|
Dec 28
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
43,798
-36.23%
|
$2,189,900
$50.5 P/Share
|
|
Dec 28
2023
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
45,225
+27.23%
|
$2,125,575
$47.34 P/Share
|
|
Dec 28
2023
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
42,525
-33.99%
|
$2,126,250
$50.19 P/Share
|
|
Dec 28
2023
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
42,525
+25.37%
|
$1,998,675
$47.34 P/Share
|
|
Dec 27
2023
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
50,000
-37.71%
|
$2,500,000
$50.23 P/Share
|
|
Dec 27
2023
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+27.38%
|
$2,350,000
$47.34 P/Share
|
|
Dec 26
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
25,000
-40.95%
|
$1,275,000
$51.46 P/Share
|
|
Dec 26
2023
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+29.05%
|
$1,175,000
$47.34 P/Share
|
|
Dec 26
2023
|
B Lynne Parshall Director |
SELL
Open market or private sale
|
Direct |
25,113
-23.32%
|
$1,280,763
$51.46 P/Share
|
|
Dec 26
2023
|
B Lynne Parshall Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,113
+18.91%
|
$1,180,311
$47.34 P/Share
|
|
Dec 26
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
20,825
-34.04%
|
$1,062,075
$51.46 P/Share
|
|
Dec 26
2023
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,825
+25.39%
|
$978,775
$47.34 P/Share
|
|
Dec 21
2023
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
17,500
-12.9%
|
$857,500
$49.29 P/Share
|
|
Dec 21
2023
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,500
+11.43%
|
$822,500
$47.34 P/Share
|